← Back

Vericel Corp Ord

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.

Price · split & dividend adjusted
News & notes moving VCEL
VCEL▲

MediWound Reaffirms 2026 Revenue Guidance of $24 Million to $26 Million

MediWound reported second quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, and reaffirmed full-year revenue guidance of $24 million to $26 million. The company said its EscharEx Phase III VLU trial is on track for interim sample size reassessment and enrollment completion by the end of the first quarter of 2027, and an updated U.S. market assessment now estimates annual peak sales of $1.05 billion for EscharEx across multiple chronic wound indications. For NexoBrid, Vericel reported its strongest quarter since launch with record revenue, hospital unit sales, and ordering centers, and MediWound entered a master service agreement with Vericel covering NexoBrid and next-generation product development. MediWound expects to begin recognizing revenue under the MSA in the second half of 2026, and it continues to advance a room temperature stable formulation of NexoBrid supported by $18.3 million in funding from the Department of War. The company reported a net loss of $7.4 million, or $0.57 per share, for the second quarter, compared with a net loss of $13.3 million, or $1.23 per share, in the prior year period.
VCEL ▲
The Motley Fool·6dRead more ▾
VCEL2

Vericel COO Michael Halpin Sells $402,000 in Stock Under Trading Plan

Vericel Chief Operating Officer Michael Halpin sold 10,000 shares of common stock for approximately $402,000 on June 18, 2026, according to an SEC filing. The sale was conducted under a trading plan adopted at the end of last year, and Halpin retains 16,248 shares directly plus 36,250 outstanding options, preserving substantial economic interest. The weighted average sale price of about $40.24 per share closely tracked the market close of $40.10. Vericel shares have risen about 10% over the past year, and the company recently reported record first-quarter revenue of $68.4 million, up 30% year over year, while raising its full-year revenue guidance by $10 million to a range of $326 million to $336 million.
VCEL
The Motley Fool·60dRead more ▾
Biotech & Genomic Medicine▲

Regenerative Medicine Market Projected to Surpass $100 Billion Within a Decade

The regenerative medicine market is projected to surpass US$100 billion within roughly a decade, driven by a shift from tissue replacement to regeneration using biomaterials, cell therapies, and 3D bioprinting. Independent estimates place the broad market in the tens of billions of dollars in 2026, with compound annual growth rates frequently estimated in the high teens to mid-20s percent. Key drivers include aging populations, the diabetes epidemic, rising surgical volumes, and growing demand in aesthetics, partly fueled by GLP-1 weight-loss medications. The sector spans profitable commercial leaders like Integra LifeSciences and Vericel to early-stage platform companies such as Conexeu Sciences, which began trading on Nasdaq in May 2026 with its collagen-based extracellular-matrix platform. Reimbursement policy and regulatory pathways remain critical risks, as illustrated by recent upheaval in the U.S. skin-substitute market affecting companies like Organogenesis and MiMedx.
MDXG ▼ORGO ▼IART ▲VCEL ▲CNXU ▲
Biotech & Genomic Medicine ▲Aging Population ▲
GlobeNewswire·69dRead more ▾
© 2026 MarketDXAsset